Praxis Precision Medicines (PRAX) said Friday it received a recommendation from an independent data monitoring committee overseeing its study 1 of the so-called Essential3 program of ulixacaltamide in essential tremor that the trial be "stopped for futility."
Truist Securities adjusted Praxis's share-price target to $85 from $175 while maintaining its buy rating.
Shares of Praxis slumped 39% following a surge in intraday trading volume to over 2.1 million from a daily average of about 363,000.
DoubleVerify (DV) reported a surprise drop late Thursday in Q4 net income, and its guidance range for Q1 sales also missed market expectations.
Goldman Sachs downgraded the company's shares to neutral from buy, with a $20 price target.
Shares of DoubleVerify sank 36%, with intraday trading volume catapulting to over 10 million versus a daily average of about 1.5 million.
NetApp (NTAP) "unexpectedly stumbled" in fiscal Q3 with revenue at the low end of guidance, and Q4 rebound expectations "muted," Wedbush Securities said Friday in a review of NetApp's earnings overnight.
Wells Fargo adjusted NetApp's share-price target to $115 from $130 while keeping its equal-weight rating.
Shares of NetApp retreated 17% as intraday trading volume surged to more than 5.5 million from a daily average of roughly 1.6 million.
Price: 39.70, Change: -25.33, Percent Change: -38.95
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。